84746-34-9

Upstream product

• 41051-15-4 4-methoxyacetoacetic acid methylester 

Downstream Products

• 907543-81-1 methyl 2-chloro-4-(methoxymethyl)thiazole-5-carboxylate 
• 929561-83-1 C₁₄H₁₃F₃N₂O₃S 
• 1222188-64-8 methyl 2-(4-chlorophenyl)-4-(methoxymethyl)thiazole-5-carboxylate 
• 933781-41-0 2-(4,4-difluoro-cyclohexyl)-4-methoxymethyl-thiazole-5-carboxylic acid methyl ester 
• 733754-08-0 methyl 2-amino-4-(methoxymethyl)thiazole-5-carboxylate 
• 154708-62-0 1-tert-Butoxycarbonylamino-4-(2-chloro-benzoyl)-2-methoxymethyl-5-methyl-1H-pyrrole-3-carboxylic acid methyl ester 

Relevant academic research and scientific papers

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals

The inventive compounds of the present invention are comprised of phenyl and pyridinyl-1,2,4-oxadiazolone derivatives and their physiologically acceptable salts and functional derivatives that are shown to provide peroxisome proliferator activator recepto

PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS

The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.